anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The control group will include 40 patients with diabetic foot ulcer receiving Standard Medical Treatment only. The Standard care of diabetic foot ulcers includes good glycemic control, adequate nutrition, off-loading (via bed rest or casts), local care (moist dressings and topical management), lessening of edema, surgical debridement of devitalized wound tissue and antibiotic therapy.
Like all medicines Spotex can cause side effects, although not everybody gets them. These might include dryness, itching, redness, peeling or oiliness. You might feel a stinging or burning sensation when you put it on your skin. Usually the effects are not serious and happen at the start of treatment. More often than not, they go away as you continue to use the gel.   
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Study participants will receive 68Ga-DOTATOC and undergo a PET/CT imaging study. Subjects may receive a second 68Ga-DOTATOC PET/CT for restaging after therapy 12-36 months following the first scan.
The invention discloses an antibacterial lipopeptide bacaucin derivative and application thereof in inhibiting bacterial infection. The antibacterial lipopeptide bacaucin derivative disclosed by the invention is polypeptide shown as SEQ ID No.4 and SEQ ID Nos. 9-18 in a sequence table or a derivative thereof. Experiments prove that the Bacaucin derivative has an inhibiting effect on bacteria. Particularly Bacaucin-1 has specific inhibition effect on staphylococcus aureus, and the minimum inhibitory concentration is 4 mug/mL; and has no cytotoxicity to Vero, HEp-2 and A549, no hemolysis, good histocompatibility and no toxicity to zebra fish embryo. The Bacaucin derivative has an inhibiting effect on gram-positive bacteria and gram-negative bacteria. It was shown that Bacaucin derivatives can be used to inhibit bacteria.
PURPOSE:A lymph-directional preparation that contains, as an active ingredient, a clathrate complex from carmofur and beta-cyclodextrin polymer, thus enabling the inhibition of cancer metastasis, because of its remarkable lymph directionality. CONSTITUTION:Carmofur, an antimetabolic anticancer agent of pyrimidine type, is clathrated with beta-cyclodextrin by, e.g., kneading to give the objective preparation. The resultant clathrate is lymph-directional, because its concentration in lymph is higher than in blood. Namely, it can be applied to a new type of therapy, in inhibition of cancer metastasis. The resulting preparation is used in the form of oral or rectal preparation or injection solution. In case of oral preparation, it is preferably combined with a lipid-surfactant mixed micell as an absorption accelerator.
<P>PROBLEM TO BE SOLVED: To provide an implantable medical device capable of being coated for minimizing or almost eliminating biological bioreaction against introduction of a medical device into a body.  <P>SOLUTION: The medical device can be coated with many biocompatible materials. A medicament, medicine or chemical compound for treatment can be mixed with the biocompatible material and fixed to at least a part of the medical device. The medicament, medicine and/or chemical compound can be utilized for treating a specific disease including fragile plaque. The drug can be delivered to the disease section. The device can be improved for promoting endothelialization. The device for delivering the implantable medical device can be improved so as to decrease the possibility of damaging the implantable medical device while disposing. Combination of various kinds of polymers can be utilized for adjusting the elution speed of the medicament, medicine and/or chemical compound for treatment from the implantable medical device.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Patients receive TG4010 SC once per week for courses 1-3 and every 2 weeks for courses thereafter and nivolumab IV over 30 minutes every 2 weeks. Courses repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Lynch syndrome (LS) is one of the most common hereditary cancer syndromes worldwide. Dominantly inherited mutation in one of four DNA mismatch repair genes combined with somatic events leads to mismatch repair deficiency and microsatellite instability (MSI) in tumours. Due to a high lifetime risk of cancer, regular surveillance plays a key role in cancer prevention; yet the observation of frequent interval cancers points to insufficient cancer prevention by colonoscopy-based methods alone. This study aimed to identify precancerous functional changes in colonic mucosa that could facilitate the monitoring and prevention of cancer development in LS.
METHODS: The study material comprised colon biopsy specimens (n = 71) collected during colonoscopy examinations from LS carriers (tumour-free, or diagnosed with adenoma, or diagnosed with carcinoma) and a control group, which included sporadic cases without LS or neoplasia. The majority (80%) of LS carriers had an inherited genetic MLH1 mutation. The remaining 20% included MSH2 mutation carriers (13%) and MSH6 mutation carriers (7%). The transcriptomes were first analysed with RNA-sequencing and followed up with Gorilla Ontology analysis and Reactome Knowledgebase and Ingenuity Pathway Analyses to detect functional changes that might be associated with the initiation of the neoplastic process in LS individuals.
FINDINGS: With pathway and gene ontology analyses combined with measurement of mitotic perimeters from colonic mucosa and tumours, we found an increased tendency to chromosomal instability (CIN), already present in macroscopically normal LS mucosa. Our results suggest that CIN is an earlier aberration than MSI and may be the initial cancer driving aberration, whereas MSI accelerates tumour formation. Furthermore, our results suggest that MLH1 deficiency plays a significant role in the development of CIN.
INTERPRETATION: The results validate our previous findings from mice and highlight early mitotic abnormalities as an important contributor and precancerous marker of colorectal tumourigenesis in LS.
FUNDING: This work was supported by grants from the Jane and Aatos Erkko Foundation, the Academy of Finland (330606 and 331284), Cancer Foundation Finland sr, and the Sigrid Jusélius Foundation. Open access is funded by Helsinki University Library.
The present invention discloses a load type iodine replenisher for molecular iodine, a preparation method and purposes. The load type iodine replenisher for molecular iodine is molecular iodine loaded by hydrotalcite. The content of iodine in the hydrotalcite is 0.5 to 5% according to the percentage by weight. The preparation method comprises: iodate anions or iodine anions are inserted into a hydrotalcite layer, or the hydrotalcite is heated to 450 to 550 DEG C so that bimetallic oxide is obtained; the property of adsorbing anions is reconstructed by utilizing the bimetallic oxide via a layer structure so as to load the iodate anions or the iodine anions; the hydrotalcite is then used as a microreactor, and iodic acid (iodate) is reduced by an iodine reducing agent so as to generate molecular iodine, or iodide is oxidized by an oxidizing agent so as to generate the molecular iodine. The problem of stability of the molecular iodine is better solved by the present invention which is suitable for industrialized production. The load type molecular iodine prepared by the present invention has the characteristics of low toxicity and high efficiency, can be used as additive of iodine replenishing feed, and can also be used for preparing health care products and medicine for human iodine replenishing and for treating human diseases by iodine with administration treatment performance.
Patients undergo three, 1-hour group therapy sessions held by a JeffQuit practitioner over a 1-month period. Patients receive strategies for managing the psychological, habitual, and physiological components of smoking and help with developing a planned quit date. Patients are also provided with advice on how to switch to cigarette brands with less nicotine and then how to substitute the nicotine patch and gum for cigarettes. The JeffQuit counselor is available for additional individual support as needed.
Using microorganisms for bioproduction requires the reorientation of metabolic fluxes from biomass synthesis to the production of compounds of interest. We previously engineered a synthetic growth switch in Escherichia coli based on inducible expression of the β- and β'-subunits of RNA polymerase. Depending on the level of induction, the cells stop growing or grow at a rate close to that of the wild-type strain. This strategy has been successful in transforming growth-arrested bacteria into biofactories with a high production yield, releasing cellular resources from growth towards biosynthesis. However, high selection pressure is placed on a growth-arrested population, favoring mutations that allow cells to escape from growth control. Accordingly, we made the design of the growth switch more robust by building in genetic redundancy. More specifically, we added the rpoA gene, encoding for the α-subunit of RNA polymerase, under the control of a copy of the same inducible promoter used for expression control of ββ'. The improved growth switch is much more stable (escape frequency <10-9), while preserving the capacity to improve production yields. Moreover, after a long period of growth inhibition the population can be regenerated within a few generations. This opens up the possibility to alternate biomass accumulation and product synthesis over a longer period of time and is an additional step towards the dynamical control of bioproduction.
OBJECTIVE: Heart failure (HF) pathophysiology in patients with obesity may be distinct. To study these features, we identified obesity-related biomarkers from 4210 circulating proteins in patients with HF with reduced ejection fraction (HFrEF) and examined associations of these proteins with HF prognosis and biological mechanisms.
METHODS: In 373 patients with trimonthly blood sampling during a median follow-up of 2.1 (25th-75th percentile: 1.1-2.6) years, we applied an aptamer-based multiplex approach measuring 4210 proteins in baseline samples and the last two samples before study end. Associations between obesity (BMI > 30 kg/m2) and baseline protein levels were analyzed. Subsequently, associations of serially measured obesity-related proteins with biological mechanisms and the primary endpoint (PEP; composite of cardiovascular mortality, HF hospitalization, left ventricular assist device implantation, and heart transplantation) were examined.
RESULTS: Obesity was identified in 26% (96/373) of patients. A total of 30% (112/373) experienced a PEP (with obesity: 26% [25/96] vs. without obesity: 31% [87/277]). A total of 141/4210 proteins were linked to obesity, reflecting mechanisms of neuron projection development, cell adhesion, and muscle cell migration. A total of 50/141 proteins were associated with the PEP, of which 12 proteins related to atherosclerosis or hypertrophy provided prognostic information beyond clinical characteristics, N-terminal pro-B-type natriuretic peptide, and high-sensitivity troponin T.
CONCLUSIONS: Patients with HFrEF and obesity show distinct proteomic profiles compared to patients with HFrEF without obesity. Obesity-related proteins are independently associated with HF outcome. These proteins carry potential to improve management of obesity-related HF and could be leads for future research.
OBJECTIVE: To develop a comprehensive framework for selecting outcomes in evaluating the clinical efficacy of Chinese herbal injections and to scientifically select outcomes for the clinical randomized controlled trial (RCT) of Tan-Re-Qing injection intervening AECOPD.
METHODS: A comprehensive literature review and consensus methods, including focus groups and Delphi surveys, were utilized.
RESULTS: Literature analysis identified 513 publications, encompassing regulatory guidance, guidelines, expert consensus, and RCTs. Initial dimensions include clinical efficacy, safety, and health economics. Primary outcomes should align with study objectives. Recommended evaluation domains include death, treatment outcome, future impact, quality of life, and safety. Commonly recommended outcomes comprise mortality, arterial blood gases, CAT, exacerbation frequency, adverse events, and lung function. Network meta-analysis identified specific therapeutic efficacy markers (white blood cell count, IL-6, IL-8). Quality of life assessment recommended SF-12, EQ-5D, or CAT. Emphasis on AECOPD frequency and lung function was noted. Delphi survey yielded 41 outcomes across various domains for evaluating Tan-Re-Qing in AECOPD.
CONCLUSION: The findings contribute to developing a robust and reliable trial design for Tan-Re-Qing injection in AECOPD. The methodology employed in this study ensures a systematic and comprehensive approach to the selection of outcomes for the clinical evaluation of future studies in this field.
Individually titrate hydromorphone hydrochloride injection [high potency formulation (HPF)] to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving hydromorphone hydrochloride injection (HPF) to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse [see Warnings and Precautions (5.2)]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration. 

If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the hydromorphone hydrochloride injection (HPF) dosage. If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.
Visit 1: Patients will be evaluated for eligibility (inclusion/exclusion checklist) and written, informed consent will be obtained. Patients will undergo general exam with vital signs. Patients will be scheduled for a fat biopsy to collect the tissue needed to grow MSC. In the event there is no cell growth from the tissue obtained from the first biopsy, one further attempt will made from a second tissue sample from this patient. However, if the second attempt fails to grow cells, no further attempts will be made, and the subject will not continue in the study.

The subjects will be subsequently followed for fistula response and closure for 24 months. Study visits are Day 1, Week 2, Week 4, Week 8, Week 12, Week 24, Week 52, and Week 104. This is an autologous product derived from the patient and used only for the same patient.
Atherosclerotic cardiovascular diseases remain a leading cause of morbidity and mortality worldwide. Atherogenesis is a slow and life-long process characterized by the accumulation of lipoproteins and immune cells within the arterial wall. Atherosclerosis has been successfully modeled in animals: However, there are economic, ethical, and translational concerns when using these models. There is also growing recognition of the need for robust human-based in vitro systems that can faithfully recapitulate key aspects of human atherosclerosis. Such systems may offer advantages in terms of scalability, reproducibility, and ability to manipulate specific variables, thereby facilitating a deeper understanding of disease mechanisms and accelerating the development of targeted therapeutics. Leveraging innovative in vitro platforms holds promise in complementing traditional animal models of atherosclerosis. In the present review, we discuss the advantages and disadvantages of recently developed models of atherosclerosis and propose ideas to be considered when developing future generations of models.
The safety and effectiveness in pediatric patients have not been established. Safety and efficacy were assessed, but not established in a dose-escalation, safety, and tolerability study (NCT00622414) in 21 patients with solid tumors 2 to 21 years of age (median age 12.9). The mean elimination half-life of free ziv-aflibercept determined after the first dose in 8 pediatric patients aged 5 to 17 years was within the range of values previously observed in adults. The maximum tolerated dose based on body weight in these pediatric patients was lower than the dose known to be safe and effective in adults with mCRC.

Juvenile Animal Toxicity Data

Weekly/every-two-weeks intravenous administration of ziv-aflibercept at dose of 3 mg per kg (approximately 0.6 times the human exposure at the 4 mg per kg dose based on AUC) to growing young adult (sexually mature) cynomolgus monkeys for up to 6 months resulted in changes in the bone (effects on growth plate and the axial and appendicular skeleton), nasal cavity (atrophy/loss of the septum and/or turbinates), kidney (glomerulopathy with inflammation), ovary (decreased number of maturing follicles, granulosa cells, and/or theca cells), and adrenal gland (decreased vacuolation with inflammation). In another study in sexually immature cynomolgus monkeys (treated intravenously for 3 months), there were similar effects. The skeletal and nasal cavity effects were not reversible after a post-dosing recovery period.
Disclosed here is a method of generating a dental recommendation based on image processing. Further, the method may include receiving at least one patient data comprising at least one image from at least one patient device. Further, the method may include retrieving at least one dental dataset. Further, the method may include analyzing the at least one patient data and the at least one dental dataset. Further, the method may include generating at least one landmark based on the analyzing. Further, the method may include retrieving at least one dental reference dataset. Further, the method may include processing the at least one landmark and the at least one dental reference dataset, determining at least one dental recommendation based on the processing, transmitting the at least one dental recommendation to at least one external device and storing the at least one dental recommendation.
Risk Summary   
Because of the potential for serious adverse reactions, including excess sedation and respiratory depression in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with hydromorphone hydrochloride extended-release tablets. Low concentrations of hydromorphone have been detected in human milk in clinical trials. Withdrawal symptoms can occur in breastfeeding infants when maternal administration of an opioid analgesic is stopped. Nursing should not be undertaken while a patient is receiving hydromorphone hydrochloride extended-release tablets since hydromorphone is excreted in the milk.

Clinical Considerations   
Monitor infants exposed to hydromorphone hydrochloride extended-release tablets through breast milk for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breast-feeding is stopped.
PURPOSE:To produce the title powder as the material for a sintered body having high strength and toughness by introducing a Zr compd., an alkaline soln., a Ca salt soln., and a phosphate soln. into a mixer from plural inlets, and subjecting the mixture to a reaction. CONSTITUTION:The soln. A contg. ammonia as the alkaline soln., the soln. B contg. a phosphate and ammonia, and the soln. C contg. a Ca salt and a Zr compd. are respectively prepared. The solns. A, B, and C are continuously introduced from the inlets 2a, 2b, and 2c of a soln. mixer 1, mixed, and subjected to a reaction. The obtained precipitate is continuously discharged from an outlet 3, filtered, washed, then dried with hot air, and pulverized by a pulverizer. By this method, the hydroxyapatite powder contg. a dispersed zirconium compd. can be easily and continuously produced.
Large-scale sequencing efforts have been undertaken to understand the mutational landscape of the coding genome. However, the vast majority of variants occur within non-coding genomic regions. We designed an integrative computational and experimental framework to identify recurrently mutated non-coding regulatory regions that drive tumor progression. Applying this framework to sequencing data from a large prostate cancer patient cohort revealed a large set of candidate drivers. We used (1) in silico analyses, (2) massively parallel reporter assays, and (3) in vivo CRISPR interference screens to systematically validate metastatic castration-resistant prostate cancer (mCRPC) drivers. One identified enhancer region, GH22I030351, acts on a bidirectional promoter to simultaneously modulate expression of the U2-associated splicing factor SF3A1 and chromosomal protein CCDC157. SF3A1 and CCDC157 promote tumor growth in vivo. We nominated a number of transcription factors, notably SOX6, to regulate expression of SF3A1 and CCDC157. Our integrative approach enables the systematic detection of non-coding regulatory regions that drive human cancers.
Participants in the yoga group received a total of eight weekly 45 minute yoga classes. A sequence of 8 - 10 core yoga poses, breathing and relaxation techniques were practiced in each yoga class, and 2 - 3 new poses were introduced progressively in each of the yoga session. Props such as blocks, blankets, belts, mats, and chairs were used during the session. Handouts were provided for participants to practice the yoga program for additional 30 minutes a day, 4 days a week at home.
Participants will receive zilebesiran on Day 1 of the 6-month double-blind (DB) treatment period. Participants must be on stable doses of at least 2, but not more than 4, antihypertensive medications for at least 30 days prior to screening and plan to remain on stable doses of these medications during screening and through the DB treatment period.
PURPOSE:To provide a granular drug composition for animal, containing a specific compound, having antibacterial activity against Gram-positive bacteria, easily handleable and administrative to animal and capable of maintaining effective blood concentration over a long period. CONSTITUTION:The objective composition contains a compound of formula I [R1 is ethyl or vinyl; (n) is 2-5; (m) is 0 or 1; X is 0, S, NR4 (R4 is H or group of formula II). etc.; R2 and R3 are alkyl or together with N atom form a heterocyclic group, etc., which may contain O, S or NR5 (R5 is alkyl, etc.), etc.] and its acid addition salt in the form supported on a zeolite and having an average particle diameter of 100-700mum, preferably 150-500mum. The zeolite may be natural or synthetic one. The natural zeolite is e.g. chabazite or mordenite and the synthetic zeolite is e.g. zeolite A or zeolite Y.